AvidBiologics

AvidBiologics is a private Canadian biotechnology company developing Antibody-Drug Conjugates (ADCs) for the treatment of cancer.

AvidBiologics is a private Canadian biotechnology company developing Antibody-Drug Conjugates (ADCs) for the treatment of cancer. AvidBiologics and its partners engineer ADCs that are highly tumour-selective. This prevents collateral damage to normal tissues and results in safe and significantly more effective cancer treatments compared to traditional chemotherapies. AvidBiologics was spun-out from YM BioSciences Inc (NYSE Amex: YMI) in 2011. The company holds rights to novel compounds previously engineered by YMI in collaboration with National Research Council of Canada - Biotechnology Research Institute (Montreal, Canada), and Fox Chase Cancer Centre (Philadelphia, USA).